Nektar Therapeutics (NKTR) Other Operating Expenses (2010 - 2026)

Nektar Therapeutics' Other Operating Expenses history runs 17 years deep, the most recent figure standing at -$44.8 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 26636.69% year-over-year to -$44.8 million; the TTM figure through Mar 2026 stood at $98.2 million (up 273.96% YoY), while the FY2025 annual figure was $9.3 million, up 56.4% from the prior year.
• Other Operating Expenses was -$44.8 million for Q1 2026 at Nektar Therapeutics, down from $142.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $142.5 million in Q4 2025 to a low of -$48.6 million in Q3 2024.
• Historically, Other Operating Expenses has averaged $19.1 million across 5 years, with a median of $9.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Other Operating Expenses jumped 1840.85% in 2023, then tumbled 26636.69% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at $15.1 million in 2022, then plunged by 45.23% to $8.2 million in 2023, then plunged by 476.49% to -$31.1 million in 2024, then soared by 558.85% to $142.5 million in 2025, then plunged by 131.47% to -$44.8 million in 2026.
• The last three Other Operating Expenses figures came in at -$44.8 million (Q1 2026), $142.5 million (Q4 2025), and $140000.0 (Q3 2025), per Business Quant data.